Dupont Capital Management Corp purchased a new stake in Quidel Co. (NASDAQ:QDEL) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,927 shares of the company’s stock, valued at approximately $655,000.
A number of other institutional investors also recently made changes to their positions in the business. Valeo Financial Advisors LLC increased its stake in Quidel by 144.9% in the second quarter. Valeo Financial Advisors LLC now owns 169 shares of the company’s stock valued at $38,000 after purchasing an additional 100 shares during the last quarter. Ameritas Investment Partners Inc. grew its position in shares of Quidel by 4.4% during the first quarter. Ameritas Investment Partners Inc. now owns 3,145 shares of the company’s stock worth $308,000 after acquiring an additional 132 shares during the last quarter. Oppenheimer Asset Management Inc. grew its position in shares of Quidel by 70.9% during the first quarter. Oppenheimer Asset Management Inc. now owns 475 shares of the company’s stock worth $46,000 after acquiring an additional 197 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of Quidel by 0.4% during the fourth quarter. Alliancebernstein L.P. now owns 49,549 shares of the company’s stock worth $3,718,000 after acquiring an additional 200 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of Quidel by 1.4% during the first quarter. Principal Financial Group Inc. now owns 15,012 shares of the company’s stock worth $1,468,000 after acquiring an additional 206 shares during the last quarter. Institutional investors own 87.02% of the company’s stock.
In other Quidel news, Director Mary Lake Ph D. Polan sold 6,700 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $204.27, for a total value of $1,368,609.00. Following the completion of the sale, the director now owns 27,484 shares of the company’s stock, valued at $5,614,156.68. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Douglas C. Bryant bought 5,000 shares of Quidel stock in a transaction on Thursday, June 11th. The stock was acquired at an average cost of $160.33 per share, with a total value of $801,650.00. Following the acquisition, the chief executive officer now owns 445,823 shares of the company’s stock, valued at approximately $71,478,801.59. The disclosure for this purchase can be found here. In the last three months, insiders sold 143,164 shares of company stock valued at $26,211,364. 14.10% of the stock is owned by corporate insiders.
NASDAQ:QDEL opened at $282.47 on Friday. The firm’s fifty day moving average price is $229.94 and its 200 day moving average price is $139.90. Quidel Co. has a 1-year low of $52.49 and a 1-year high of $287.88. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.10 and a quick ratio of 1.67. The firm has a market cap of $11.86 billion, a price-to-earnings ratio of 137.79 and a beta of 1.16.
Quidel (NASDAQ:QDEL) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Quidel had a net margin of 15.73% and a return on equity of 23.69%. The firm had revenue of $174.65 million for the quarter, compared to analyst estimates of $157.12 million. As a group, analysts expect that Quidel Co. will post 7.25 earnings per share for the current fiscal year.
A number of equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. lowered shares of Quidel from a “neutral” rating to an “underweight” rating and raised their target price for the stock from $120.00 to $158.00 in a research report on Tuesday, May 12th. Craig Hallum raised their target price on shares of Quidel from $306.00 to $363.00 and gave the stock a “buy” rating in a research report on Friday. Piper Sandler raised their target price on shares of Quidel from $250.00 to $360.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Zacks Investment Research lowered shares of Quidel from a “buy” rating to a “hold” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. Quidel currently has an average rating of “Hold” and a consensus price target of $177.29.
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
Want to see what other hedge funds are holding QDEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quidel Co. (NASDAQ:QDEL).
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.